3-(1-哌啶基甲基)苯胺 | 93138-55-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(1-哌啶基甲基)苯胺
• 中文别名: 3-(哌啶-1-甲基)苯胺；3-(哌啶基甲基)苯胺
• 英文名称: 3-(piperidin-1-ylmethyl)aniline
• CAS: 93138-55-7
• 化学式: C₁₂H₁₈N₂
• mdl: MFCD04114502
• 分子量: 190.288
• InChiKey: SEJNYLBEEMVJNN-UHFFFAOYSA-N

物化性质

• 熔点：
  106 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933399090
• 储存条件：
  室温且干燥

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-(Piperidin-1-ylmethyl)aniline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-(Piperidin-1-ylmethyl)aniline
CAS number: 93138-55-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H18N2
Molecular weight: 190.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(1-哌啶基甲基)苯胺 在 硫酸 、 potassium iodide 、 sodium hydroxide 、 sodium nitrite 作用下， 以 水 、 二甲基亚砜 为溶剂， 反应 20.0h， 生成 罗沙替丁
  参考文献：
  名称：

  罗沙替丁醋酸酯盐酸盐的中间体3-(1-哌啶甲 基)苯酚的制备方法

  摘要：

  本发明涉及一种罗沙替丁醋酸酯盐酸盐的中间体——3‑(1‑哌啶甲基)苯酚的制备方法。以间硝基苯甲醛为起始原料，在相转移催化剂作用下，经金属硼氢化物还原剂还原得到相应的苄醇；在碱存在的条件下，与有机磺酰氯类物质反应生成含活性的有机磺酸酯；再在碱存在的条件下与哌啶经N‑烷基化反应得到N‑取代哌啶衍生物；再将其中的硝基还原得到相应的氨基化合物；此氨基化合物在硫酸水溶液介质中经重氮化后再水解、碱化后得到3‑(1‑哌啶甲基)苯酚。本发明解决了传统合成原料间羟基苯甲醛供应不足以至合成罗沙替丁醋酸酯盐酸盐的成本大幅提高的问题，本发明方法简便而安全、各反应原料价廉易得、反应收率高、尤其是适于工业化生产3‑(1‑哌啶甲基)苯酚。

  公开号：

  CN107698538B
• 作为产物：
  描述：

  3-硝基苯甲醇 在 氢气 、 sodium hydroxide 作用下， 以 甲醇 为溶剂， 20.0~50.0 ℃ 、303.99 kPa 条件下， 生成 3-(1-哌啶基甲基)苯胺
  参考文献：
  名称：

  罗沙替丁醋酸酯盐酸盐的中间体3-(1-哌啶甲 基)苯酚的制备方法

  摘要：

  本发明涉及一种罗沙替丁醋酸酯盐酸盐的中间体——3‑(1‑哌啶甲基)苯酚的制备方法。以间硝基苯甲醛为起始原料，在相转移催化剂作用下，经金属硼氢化物还原剂还原得到相应的苄醇；在碱存在的条件下，与有机磺酰氯类物质反应生成含活性的有机磺酸酯；再在碱存在的条件下与哌啶经N‑烷基化反应得到N‑取代哌啶衍生物；再将其中的硝基还原得到相应的氨基化合物；此氨基化合物在硫酸水溶液介质中经重氮化后再水解、碱化后得到3‑(1‑哌啶甲基)苯酚。本发明解决了传统合成原料间羟基苯甲醛供应不足以至合成罗沙替丁醋酸酯盐酸盐的成本大幅提高的问题，本发明方法简便而安全、各反应原料价廉易得、反应收率高、尤其是适于工业化生产3‑(1‑哌啶甲基)苯酚。

  公开号：

  CN107698538B

文献信息

• [EN] QUINOLONE CARBOXYLIC ACID DERIVATIVES FOR TREATMENT OF HYPERPROLIFERATIVE CONDITIONS<br/>[FR] DERIVES D'ACIDE CARBOXYLIQUE DE QUINOLONE POUR LE TRAITEMENT DES TROUBLES HYPERPROLIFERATIFS
  申请人：BAYER PHARMACEUTICALS CORP

  公开号：WO2005097752A1

  公开（公告）日：2005-10-20

  Quinolone carboxylic acid derivatives of formula (I) wherein Ar is an optionally substituted phenyl, pyridyl, or pyrimidinyl group and the substituent groups R1, R4, R10, R11, R19, and R20 are as defined in the specification, pharmaceutical compositions containing them, and methods of using them in treatment of hyperproliferative diseases such as cancer are disclosed and claimed.

  公开和声明了式(I)的喹诺酮羧酸衍生物，其中Ar是可选择地取代的苯基、吡啶基或嘧啶基，取代基R1、R4、R10、R11、R19和R20如规范中定义，包含它们的药物组合物，以及在治疗癌症等高增殖性疾病中使用它们的方法。
• Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
  申请人：——

  公开号：US20040092538A1

  公开（公告）日：2004-05-13

  The present invention relates to a class of compounds represented by the Formula I 1 or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively inhibiting or antagonizing the &agr; v &bgr; 3 and/or &agr; v &bgr; 5 integrin.

  本发明涉及一类由公式I代表的化合物 1 或其药用可接受的盐，包含公式I化合物的药物组合物，以及选择性地抑制或拮抗α v β 3 和/或α v β 5 整合素的方法。
• Pyrazole compounds
  申请人：——

  公开号：US20030060453A1

  公开（公告）日：2003-03-27

  Pharmaceutical compositions and compounds are provided. The compounds of the invention demonstrate anti-proliferative activity, and may promote apoptosis in cells lacking normal regulation of cell cycle and death. In one embodiment of the invention, pharmaceutical compositions of the compounds in combination with a physiologically acceptable carrier are provided. The pharmaceutical compositions are useful in the treatment of hyperproliferative disorders, which disorders include tumor growth, lymphoproliferative diseases, angiogenesis. The compounds of the invention are substituted pyrazoles and pyrazolines.

  提供药物组合物和化合物。发明的化合物显示出抗增殖活性，并且可能促进缺乏正常细胞周期和死亡调控的细胞的凋亡。发明的一个实施例提供了化合物与生理可接受载体组合的药物组合物。该药物组合物可用于治疗过度增殖障碍，包括肿瘤生长、淋巴增殖性疾病、血管生成。发明的化合物是取代吡唑和吡唑啉。
• [EN] IMIDAZO [1,2-B] PYRIDAZINE DERIVATIVES FOR THE TREATMENT OF C-MET TYROSINE KINASE MEDIATED DISEASE<br/>[FR] DÉRIVÉS D'IMIDAZO[1,2-B]PYRIDAZINE POUR LE TRAITEMENT DE MALADIES MÉDIÉES PAR LA TYROSINE KINASE C-MET
  申请人：NOVARTIS AG

  公开号：WO2009106577A1

  公开（公告）日：2009-09-03

  The invention relates to compounds of formula (I) and salts thereof, formula (I) wherein the substituents are as defined in the specification, the application of a compound of formula (I) in a process for the treatment of the human or animal body, in particular with regard to C-Met tyrosine kinase mediated disease; the use of a compound of formula (I) for manufacturing a medicament for the treatment of such diseases; pharamaceutical compositions comprising a compound of the formula (I), optionally in the presence of a combination partner; processes for the preparation of a compound of formula (I).

  该发明涉及式(I)化合物及其盐，式(I)中取代基如规范中所定义，式(I)化合物在用于治疗人体或动物体内的过程中的应用，特别是涉及C-Met酪氨酸激酶介导的疾病；式(I)化合物用于制造治疗此类疾病的药物；包含式(I)化合物的药物组合物，可选地与组合伙伴一起；式(I)化合物的制备方法。
• Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof
  申请人：Tsou Hwei-Ru

  公开号：US20080085890A1

  公开（公告）日：2008-04-10

  This invention provides compounds of Formula (I), having the structure where G 1 , G 2 , G 3 , G 4 , A 1 , A 2 , Y 1 , Y 2 , L 1 , Z, e and f are defined herein, or a pharmaceutically acceptable salt thereof, which are useful for treating or preventing cancer.

  这项发明提供了具有结构的化合物（I），其中G1、G2、G3、G4、A1、A2、Y1、Y2、L1、Z、e和f在此处定义，或其药用可接受盐，用于治疗或预防癌症。